Login to Your Account

Other News To Note

Wednesday, June 27, 2012
• Gentium SpA, of Villa Guardia, Italy, said it submitted its responses to the Day 180 list of outstanding issues received from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription